• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • More
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia.
 

The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia.

Options
  • Details
  • Files
BORIS DOI
10.48350/173354
Publisher DOI
10.1186/s12959-022-00411-0
PubMed ID
36163073
Description
In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis of HIT is based on the combination of clinical parameters, allowing to determine the pretest probability, and laboratory testing for anti-PF4/heparin antibodies and confirmatory functional assays, such as the heparin-induced platelet activation (HIPA) test.We report the case of a patient with severe Covid-19 pneumonia requiring ECMO treatment, who developed recurrent clotting of the ECMO filter and a drop in platelet count under heparin treatment. He was therefore suspected to have HIT and the anticoagulation was switched to argatroban. Despite high clinical probability and high titres of anti-PF4/heparin antibodies, the functional HIPA test was negative. Nevertheless, argatroban was continued rather than to reinstate anticoagulation with heparin. Reevaluation 7 days later then demonstrated a strongly positive functional HIPA test and confirmed the diagnosis of HIT. Under anticoagulation with argatroban the patient gradually improved and was finally weaned off the ECMO.In conclusion, this case highlights the critical importance of clinical judgement, exploiting the 4 T score, given that Covid-19 patients may present a different pattern of routine laboratory test results in HIT diagnostics. The possibility of a false negative HIPA test has to be considered, particularly in early phases of presentation. In cases of a discrepancy with high clinical probability of HIT and/or high titre anti-PF4/heparin antibodies despite a negative HIPA test, a reevaluation within 3 to 5 days after the initial test should be considered in order to avoid precipitant reestablishment of unfractionated heparin, with potentially fatal consequences.
Date of Publication
2022-09-26
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
Covid-19 Heparin-induced platelet activation test Heparin-induced thrombocytopenia
Language(s)
en
Contributor(s)
Draxler, Dominik Ferdinand
Universitätsklinik für Kardiologie
Brodard, Justine
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Zante, Björn
Universitätsklinik für Intensivmedizin
Jakob, Stephan
Universitätsklinik für Intensivmedizin
Wiegand, Jan Alexander Andreas
Universitätsklinik für Intensivmedizin
Kremer Hovinga Strebel, Johanna Annaorcid-logo
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Angelillo, Anne
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Rovó, Alicia
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Additional Credits
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Universitätsklinik für Intensivmedizin
Universitätsklinik für Kardiologie
Series
Thrombosis journal
Publisher
BioMed Central
ISSN
1477-9560
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: ae9592 [15.12. 16:43]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo